
    
      Study 301OTC02 is a long-term follow-up study to evaluate the safety and efficacy of
      adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of human OTC in adults
      with late-onset OTC deficiency. Only subjects who complete Study 301OTC01 (NCT02991144) are
      eligible to participate in Study 301OTC02.
    
  